Horizon Pharma plc (NASDAQ:HZNP) has tumbled 7.38% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 9.02% in the last four weeks. The stocks have underperformed the S&P 500 by 6.27% during the past week but Horizon Pharma plc (NASDAQ:HZNP) it has outperformed the index in 4 weeks by 8.02%.
Horizon Pharma plc (NASDAQ:HZNP): The stock opened at $17.45 on Friday but the bulls could not build on the opening and the stock topped out at $17.46 for the day. The stock traded down to $16.51 during the day, due to lack of any buying support eventually closed down at $16.56 with a loss of -4.99% for the day. The stock had closed at $17.43 on the previous day. The total traded volume was 3,777,370 shares.
The company shares have dropped -52.01% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $39.49 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $16.12 and the 200 Day Moving Average price is recorded at $17.50.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Nohria Virinder, director of Horizon Pharma Plc, had unloaded 25,000 shares at an average price of $17.69 in a transaction dated on June 15, 2016. The total value of the transaction was worth $442,250.
Many analysts have stated their opinion on the company shares. Goldman Sachs initiates coverage on Horizon Pharma plc (NASDAQ:HZNP).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Goldman Sachs announces the price target of $24 per share. The rating by the firm was issued on June 6, 2016. Currently the company Insiders own 2.1% of Horizon Pharma plc shares according to the proxy statements. Institutional Investors own 86.84% of Horizon Pharma plc shares. During last six month period, the net percent change held by insiders has seen a change of -2.67%.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.